Drug makers increased their payments to doctors and organizations in the U.K. by a whopping 25 percent last year — to about $590 million — from the year before, thanks in part to a rise in R&D grants, according to figures released by a pharmaceutical industry trade group.
However, the data is incomplete, because only 65 percent of physicians consented to share payment details. Although the disclosure rate was up from 55 percent in 2015, the skimpy showing is likely to maintain pressure on drug makers and doctors to provide more transparency.
About the Author Reprints
